vadadustat achieved positive results in a number of Phase 3 trials for patients with renal anemia
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
March 13, Akebia Therapeutics(http://announced that the company's development of vadadustat, developed jointly with Mitsubishi MitsubishiPharmaceutical(http://Corporation (MTPC), had achieved positive results in theof a number of phase 3trial
s (http:// for patients with renal anemiaVadadustat
Vadadustat is an oral hypoxic-inducing factor protalysine inhibitor (HIF-PHI)MTPC is expected to submit an application fornew drug(http://in Japan later this yearVadadustat's role is to simulate the body's physiological response to hypoxia at high altitudesAt high altitudes, the body's response to the scarcity of oxygen is to increase hIF production HIF regulates the mobilization of iron and the production of EPO to stimulate the production of red blood cells, thereby improving oxygen transport if approved, Vadadustat will provide patients with an oral treatment option and could become a new standard treatment for patients with renal anemia In a randomized, open labeled, active control Phase 3 clinical trial called J01, 304 non-dialysis-dependent renal anemia patients received vadadustat and an ESA treatment The results showed that after 24 weeks of treatment, the study reached its main endpoint Hemoglobin levels in the Vadadustat patient group met non-performance standards compared to the active control group In the J03 randomized double-blind, active control Phase 3 clinical trials treating patients with dialysis-dependent renal anemia, vadadustat also reached the main end of the trial and reached the non-adverse standard compared to ESA About renal anemia
renal anemia is a common complication of chronic kidney disease (CKD) The kidneys are an important organ for the production of red blood cell oxytocin (EPO), which stimulates the production of red blood cells in the bone marrow renal anemia is due to decreased renal function, on the one hand, the production of EPO decreased, on the other hand, the kidneys of anemia caused by hypoxia stimulation can not produce an adequate response
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.